MdxHealth (TM) : MDxHealth's ConfirmMDx(TM) Test Outperforms PSA in Prostate Cancer Detection Algorithm and Decision for Repeat Biopsy Presentations at 2013 American Urology Association Annual Meeting Discuss How ConfirmMDx for Prostate Cancer and Detection Algorithm Helps Men Avoid Unnecessary Repeat Prostate Biopsies and Aid Urologists to Improve Patient Management IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, April 22, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced two presentations on ConfirmMDx for Prostate Cancer, its test to help urologists rule-out prostate cancer-free men from undergoing unnecessary repeat biopsies, at the upcoming 2013 American Urology Association (AUA) Annual Meeting in San Diego, CA (May 4-8, 2013). An abstract on the role of ConfirmMDx has been chosen for the "Late-Breaking Science Forum" and key urology experts will present data on the test as part of a panel discussion on novel molecular biomarkers for prostate cancer. "Late-Breaking Science Forum" Podium Presentation at AUA In an oral presentation, Prof Wim Van Criekinge will describe how combining the epigenetic ConfirmMDx for Prostate Cancer test with traditional histopathological results and other risk factors, including PSA screening, was shown to improve patient management by helping to stratify men who may avoid unnecessary repeat biopsies from those who may harbor undetected prostate cancer and who merit early repeat biopsy. Title: "A Model Combining Traditional Risk Factors with Epigenetic Profiling Avoids Unnecessary Repeat Biopsies" Presentedby: Prof Wim Van Criekinge, Head of the Laboratory for Computational Genomics and Bioinformatics (Biobix), University of Ghent, Belgium Date: Tuesday, May 7th, 2013 Time: 1:00 - 2:30 pm Location: SDCC 6C, San Diego Convention Center Clinical Update on Novel Prostate Cancer Biomarkers Experts in the field of urology, Dr. David Crawford and Dr. Neal Shore will discuss the role new molecular biomarkers, such as MDxHealth's ConfirmMDx and Genomic Health's Oncotype DX, will play in the diagnosis and staging of prostate cancer. The program is supported by the Prostate Conditions Education Council, a consortium of leading physicians, health educators, scientists and prostate cancer advocates, and is intended to outline the clinical utility of these new molecular tests and how they will aid in the improved detection and treatment of prostate cancer. Title: "Understanding How New Biomarkers Will Assist in the Diagnosis and Prognosis of Prostate Cancer" Presentedby: E. David Crawford, M.D., Head Section of Urologic Oncology, Professor of Urology, Surgery and Radiation Oncology, University of Colorado School of Medicine, Denver, Colorado Neal D. Shore, M.D., FACS, Director, CPI, Carolina Urologic Research Center, Grand Strand Urology/Atlantic Urology Clinics, Myrtle Beach, South Carolina Date: Tuesday, May 7th, 2013 Time: 10 am Location: Industry Theatre, Exhibit Hall, San Diego Convention Center About ConfirmMDx for Prostate Cancer Over 650,000 American men receive a negative prostate biopsy result each year; though approximately 25% of these men may still harbor occult prostate cancer. This well-documented risk of undetected cancer, often with clinically significant Gleason scores, leads to a high rate of repeat biopsies with over 40% of men receiving at least one repeat biopsy, and many receiving a 3^rd and 4^th biopsy. Today's gold standard diagnostic approach is the prostate biopsy procedure, collecting 10-12 needle core biopsy samples, however this sampling represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level. This molecular "halo" around a cancer lesion can be present despite having a normal appearance under the microscope. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. About MDxHealth MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDx^TM for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth's website at www.mdxhealth.com. For more information: Dr Jan Groen President and CEO Mike Sinclair Seth Lewis MDxHealth Halsin Partners The Trout Group US: +1 949 812 6979 UK: +44 20 7318 2955 US: +1 646 378 2952 BE: +32 4 364 20 70 Cell: +44 7968 022075 firstname.lastname@example.org email@example.com firstname.lastname@example.org This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws. NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners. Clik here to access the PDF version ------------------------------------------------------------------------------ This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: MdxHealth (TM) via Thomson Reuters ONE HUG#1694495
MdxHealth (TM) : MDxHealth's ConfirmMDx(TM) Test Outperforms PSA in Prostate Cancer Detection Algorithm and Decision for Repeat
Press spacebar to pause and continue. Press esc to stop.